- SGX Pharmaceuticals Announces Strategic Collaboration To Develop And Commercialize BCR-ABL Inhibitor
- To End or Not to End Your Relationship?
- How To Get The Most Out Of Your Email Marketing Software
- High Growth Stock Purchase – Case Study: True Religion (TRLG)
- Guide to Cell Phone Ringtones
- Domestic Abuse Affects Everyone
- Pointers for Pet Medication
- Simple Tips On Finding Free Dog Training
- Forex: Online Trading Safety: Why Some Trading Experts Risk Their Own Money When Teaching This Important Trading Tip
- Air Purifier Info for Dummies
inhibitor
SGX Pharmaceuticals Announces Strategic Collaboration To Develop And Commercialize BCR-ABL Inhibitor
Under the terms of the agreement, SGX will receive from Novartis $25 million in upfront payments and the purchase of SGX common stock. Along with success-based milestones, but excluding royalties, total payments to SGX could exceed $515 million, including a minimum of two years of research funding. The success of Gleevec(TM) (imatinib), the first targeted [...]